Baird Reiterates a 'Neutral' on Regeneron Pharma (REGN); VIEW 2-Year Data Blurs EYLEA's Differentiation, As Expected

Baird reiterates a 'Neutral' on Regeneron Pharma (NASDAQ: REGN) price target of $56.00.

Baird analyst says, "With 2-year VIEW data showing a continued slight efficacy advantage for Lucentis, yet a significant narrowing of dosing frequency between EYLEA and Lucentis, we think net-net, Roche's marketing efforts got a slight boost as a result of today's release. As such, with price now an increasing prominent distinction, we continue to want to watch this launch from the sidelines."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $58.28 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating